<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310492</url>
  </required_header>
  <id_info>
    <org_study_id>SHX0556</org_study_id>
    <nct_id>NCT00310492</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis</brief_title>
  <official_title>Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study to Demonstrate the Efficacy of a 12-month Subcutaneous Specific Immunotherapy With ALK-depot SQ Milbenmischung in Patients With Atopic Dermatitis and Proven IgE-mediated Sensitization to House Dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment
      of atopic dermatitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in SCORAD and topical medication consumption</measure>
    <time_frame>1 year</time_frame>
    <description>Sccore of atopic dermatitis (SCORAD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in SCORAD intensity score, EASI score and change in topical medication consumption</measure>
    <time_frame>1 year</time_frame>
    <description>Eczema Area Severity Index (EASI)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SCORAD extent criteria, index, subjective symptoms, IGA score, oral rescue medication, exacerbation of atopic dermatitis, DLQI, treatment expectation questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>Investigator´s Global Assessment (IGA), Dermatology Life Quality Index (DLQI)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Subcutaneous immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>subcutaneous immunotherapy</intervention_name>
    <description>Updosing by 16 injections to 100,000 SQ-U</description>
    <arm_group_label>Subcutaneous immunotherapy</arm_group_label>
    <arm_group_label>Subcutaneous injections</arm_group_label>
    <other_name>ALK-depot SQ mites</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive specific IgE to house dust mites

          -  Atopic dermatitis according to Hanifin/Rajka

          -  Chronic course of Atopic dermatitis

          -  SCORAD larger than 25 points

        Exclusion Criteria:

          -  Erythrodermia

          -  Syst.treatment with gcs or immunosuppressive agents in the prev.4 weeks

          -  History of specific immunotherapy with mites

          -  UV radiation

          -  Group 4 topical corticosteroids (European classification)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Wolf, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ALK-SCHERAX Arzneimittel GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Kapp, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Hannover</city>
        <zip>D-30449 Hannover</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2006</study_first_submitted>
  <study_first_submitted_qc>April 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

